跳转至内容
Merck
CN

SHC004V

Sigma-Aldrich

MISSION® TurboGFP shRNA Control Transduction Particles

shRNA sequence targeting tGFP

别名:

MISSION®

登录查看公司和协议定价


About This Item

UNSPSC代码:
41106609
NACRES:
NA.51

质量水平

产品线

MISSION®

浓度

≥1x106 VP/ml (via p24 assay)

技术

capture ELISA: 106 TU/mL using p24

运输

dry ice

储存温度

−70°C

正在寻找类似产品? 访问 产品对比指南

一般描述

The MISSION TurboGFP shRNA Control Transduction Particles contain an shRNA sequence targeting TurboGFP. The TurboGFP shRNA Control Particles are useful as a positive knockdown control in experiments using the MISSION TurboGFP positive control vector or in cell lines expressing TurboGFP. TurboGFP is an improved variant of the green fluorescent protein copGFP cloned from copepoda Pontellina plumata.
The TurboGFP shRNA control transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro-TurboGFP shRNA (SHC004). Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. In addition, the Control Transduction Particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells. 200 μl of 106 TU/ml (via p24 titering assay) lentiviral particles are provided as frozen stock.
当使用MISSION® TRC shRNA克隆进行实验时,选择适当对照品是您的实验设计的关键要素,以便准确解释敲低结果。 MISSION对照转导颗粒是监测转导效率的关键阳性对照。
想要查看更多应用数据、实验方案和载体图谱,请访问 sigma.com/shrna

应用

To see more application data, protocols, vector maps visit sigma.com/shrna.

法律信息

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
TurboGFP is a trademark of Evrogen Co.

储存分类代码

12 - Non Combustible Liquids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mariano J Alvarez et al.
Nature genetics, 50(7), 979-989 (2018-06-20)
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门